The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
MitaA., DenisL., RowinskyE.. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res.2009; 15(2): 723–730.
3.
SartorA., OudardS., OzgurogluM.. Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: final results of a multinational phase III trial (TROPIC) [abstract 9]. Presented at: American Society of Clinical Oncology Genitourinary Cancers Symposium; June 4-8, 2010; Chicago, IL. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=73&abstractID=30560. Accessed September 3, 2010.
4.
PivotX., KoralewskiP., HidalgoJ.. A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol.2008; 19(9): 1547–1552.
5.
Jevtana [package insert].Bridgewater, NJ: sanofiaventis U.S. LLC; 2010.
HodiF.S., O'DayS.J., McDermottD.F.. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med.2010; 363(8): 711–723.
8.
SmallE.J., TchekmedyianN.S., RiniB.I.. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res.2007; 13(6): 1810–1815.
9.
Medarex, Inc. A randomized, double-blind, multicenter study comparing MDX-010 monotherapy, MDX-010 in combination with a melanoma peptide vaccine, and melanoma vaccine monotherapy in HLA-A*0201-positive patients with previously treated unresectable stage III or IV melanoma: protocol no. MDX010-20. http://0-www.nejm.org.opac.uthsc.edu/doi/suppl/10.1056/NEJMoa1003466/suppl_file/nejmoa1003466_protocol.pdf. Accessed September 3, 2010.
10.
WolchakJ.D., NeynsB., LinetteG.. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomized, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol.2010; 11(2): 155–164.
11.
WeberJ.S., O'DayS., UrbaW.. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol.2008; 26(36): 5950–5956.
WeberJ., ThompsonJ.A., HamidO.. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res.2009;15(17): 5591–5598.
14.
KuG.Y., YuanJ., PageD.B.. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting. Cancer.2010; 116(7): 1767–1775.
